In patients with stage IB‐IIIA resectable NSCLC who may or may not have received standard adjuvant chemotherapy after complete surgical resection, pembrolizumab resulted in a significantly longer disease‐free survival compared with placebo irrespective of PD‐L1 expression [20], which supported the integration of pembrolizumab as an adjuvant monotherapy in the management of resectable NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.